Evaluation of Clinical Effectiveness and Safety of Locaste 8F Guiding Catheter in Neurovascular Interventional Surgery

The Locaste 8F Delivery Catheter by Kai MedTech has been launched in China since 2022 and has been widely used clinically. It won the government tendering in many provinces in China in early 2024. As a guiding and access device, the investigational device is used in interventional surgeries. The clinical investigation plans to conduct a non-interventional post-marketing real-world study to evaluate the safety and effectiveness of the product in clinical use. The investigator shall use the Locaste 8F Guiding Catheter according to his own surgery plan and the instruction for use (IFU) of this device. The large-bore guiding catheters (also called as long guiding sheath) by global manufacturers are generally used. Locaste 8F Guiding Catheter is marketed in China and widely accepted in clinical application. By collecting data in the real-world clinical routine treatment, the effectiveness and the safety of Locaste 8F Guiding Catheter is evaluated to provide data support of further global use of this device.

Study Overview

• Status: Completed
• Conditions: Stroke; Hemorrhagic Strokes

Detailed Description

This clinical investigation is a single-arm, retrospective, multicenter clinical study of a medical device marketed in China. Patients with Locaste 8F Guiding Catheter used in the neurovascular interventional surgery and the surgery video of the Locaste 8F Guiding Catheter available are recruited in this study. The data on the surgery day and follow-up data within 24 hours after surgery are collected retrospectively.

This clinical investigation will be performed in accordance with the Declaration of Helsinki [5] and the applicable parts of ISO 14155：2020 Clinical investigation of medical devices for human subjects - Good clinical practice made by International Organization for Standardization except for section 5.8 informed consent and other non-relevant aspects for retrospective study. The ethic approval was achieved with the exemption of informed consent according to the local China regulations "The Guidelines for the Establishment of Ethical Review Committees for Clinical Research Involving Humans", article 5 Exemption of Informed consent.

Since this clinical investigation is a non-interventional post-market study with the intended use of the investigational device in China, this study does not apply to the scope of pre-market clinical investigation for medical device approval defined in the Medical Device Good Clinical Practice (2022) issued by the China NMPA . Thus, this clinical investigation only refers to the applicable part of the Medical Device Good Clinical Practice (2022) issued by the China NMPA.

Given the fact that this clinical investigation is a retrospective study, any serious adverse event (SAE) should have been reported according to the regulation Procedure for Monitoring and Re-evaluation of Medical Device Adverse Event (2018). No serious adverse events in this study shall be reported again. In case of any underreporting, the investigator shall report the serious adverse events according to the Procedure for Monitoring and Re-evaluation of Medical Device Adverse Event (2018).

The intended use of the investigational device approved in China is that "The device is indicated for the introduction of interventional devices into the peripheral, coronary, and neuro vasculature". The subject cohort in this clinical investigation is covered by the device use scope.

• Study Type: Observational
• Enrollment (Actual): 113

Contacts and Locations

Study Locations

• China
  • Henan
    • Xinxiang, Henan, China, 453000
      • Xinxiang City Central Hospital
    • Zhumadian, Henan, China, 463000
      • Zhumadian City Central Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Patients undertaken a neurovascular intervention surgery procedure including Locaste 8F Guiding Catheter in a reverse chronological order earlier than the date of the ethic approval.

Description

Inclusion Criteria:

• Age of 18 years or older;
• Undertaken a neurovascular surgery procedure including Locaste 8F Guiding Catheter;
• Available images of Locaste 8F Guiding Catheter in the neurovascular surgery;

Exclusion Criteria:

• Disorders of vascular fragility (e.g. Ehlers-Danlos syndrome)
• Prior vascular dissection or injury to vessels to be catheterized

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
Locaste 8F Guiding Catheter in Neurovascular interventional surgery; Patients with Locaste 8F Guiding Catheter used in the neurovascular interventional surgery and the surgery video of the Locaste 8F Guiding Catheter available are recruited in this study.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Device Success Rate	Definition：Number of Patients with Device Success / Number of Recruited Patients * 100% Device Success： Use 5-Point Likert Scale to evaluate the navigability of device to the targeted vessel position.; Unsatisfactory；; Unacceptable；; Adequate；; Good;; Excellent； Device success is defined as the score ≥3.	Day 0 （During surgery）

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Ability to deliver other interventional devices	Definition：the incidence of score ≥3: Ability to deliver other interventional devices is defined the satisfactory rate of the ability to deliver other interventional devices. Use 5-Point Likert Scale to evaluate the ability to deliver other interventional devices.; Unsatisfactory；; Unacceptable；; Adequate；; Good；; Excellent；	Day 0（During surgery）
Visibility under X-ray	Definition：Visibility under X-ray: the incidence of score ≥3； Visibility under X-ray is defined as the satisfactory rate of the visibility under X-ray. Use 5-Point Likert Scale to evaluate the Visibility under X-ray.; Unsatisfactory；; Unacceptable；; Adequate；; Good；; Excellent；	Day 0（During surgery）
Ability to support other interventional devices	The incidence to achieve satisfactory support of other interventional devices.	Day 0（During surgery）
Device Deficiency	For all the subjects who have completed the surgery, no defects of the investigational device were found. One patient did not complete the surgery and no defects of the investigational device were found during the use.	Day 0 (During surgery)
Adverse Event (AE)	For all the subjects who have completed the surgery, no adverse events were found. One patient did not complete the surgery and no adverse events were found during the use.	Day 0(during surgery) or Day 1 (within 24 hours after the surgery)

Collaborators and Investigators

• Sponsor: Keuro MedTech

Study record dates

Study Major Dates

• Study Start (Actual): May 21, 2024
• Primary Completion (Actual): October 7, 2024
• Study Completion (Actual): October 7, 2024

Study Registration Dates

• First Submitted: March 21, 2025
• First Submitted That Met QC Criteria: March 31, 2025
• First Posted (Actual): April 8, 2025

Study Record Updates

• Last Update Posted (Actual): June 24, 2025
• Last Update Submitted That Met QC Criteria: June 18, 2025
• Last Verified: June 1, 2025

More Information

Terms related to this study

• Keywords: Guiding catheter; Locaste; Long sheath
• Additional Relevant MeSH Terms: Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases; Hemorrhagic Stroke; Stroke
• Other Study ID Numbers: CIP-PICA-RWD

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No